Figure 2. Inhibition of FLT3 AL mutant phosphorylation by FLT3 TKI.

BaF3 cells expressing FLT3 AL mutations were treated with either a. midostaurin, b. lestaurtinib, c. crenolanib or d. ponatinib at the indicated concentrations for 1 h at 37°C followed by immunoprecipitation for FLT3, SDS-PAGE and WB for FLT3 and phospho-FLT3 (PFLT3). Each experiment was performed at least twice and representative results are shown.